The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The Punjab government reportedly launched SANGAT Mental Health Clubs in 40 colleges on 22 October…
Indian para-badminton players Nitesh Kumar and Naveen Sivakumar reportedly won men’s singles gold medals at…
Greece’s Parliament reportedly approved legislation on 23 October 2026 to prohibit children under 15 from…
A Kochi-based architecture student won the 28th Charles Correa Gold Medal in Mumbai on October…
Ameena Nazreen A S received a US$500 cash award at the Global Youth Institute on…
Indian table tennis players Yashaswini Ghorpade and Harmeet Desai secured a medal in mixed doubles…